170 related articles for article (PubMed ID: 8644642)
1. Short-term hemodynamic, anti-ischemic, and antianginal effects of pirsidomine, a new sydnonimine.
Stengele E; Ruf G; Jähnchen E; Trenk D; Löffler K; Schulz W; Roskamm H
Am J Cardiol; 1996 May; 77(11):937-41. PubMed ID: 8644642
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of the new nitric oxide donor, pirsidomine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs.
Bohn H; Martorana PA; Schönafinger K
Eur J Pharmacol; 1992 Sep; 220(1):71-8. PubMed ID: 1425982
[TBL] [Abstract][Full Text] [Related]
3. Antiischemic effects of pirsidomine, a new nitric oxide donor.
Martorana PA; Kettenbach B; Bohn H; Schönafinger K; Henning R
Eur J Pharmacol; 1994 May; 257(3):267-73. PubMed ID: 8088346
[TBL] [Abstract][Full Text] [Related]
4. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study.
Sellier P; Broustet JP
Am J Cardiovasc Drugs; 2003; 3(5):361-9. PubMed ID: 14728070
[TBL] [Abstract][Full Text] [Related]
5. Clinical and hemodynamic effects of the new dilator drug molsidomine.
Malcolm AD
Am Heart J; 1985 Mar; 109(3 Pt 2):674-7. PubMed ID: 3883734
[TBL] [Abstract][Full Text] [Related]
6. [Effect of intravenous diltiazem on stress-induced myocardial ischemia (study of hemodynamics and reproducibility of repeated studies].
Schnellbacher K; Hirsch F; Stengele E; Roskamm H
Z Kardiol; 1988 Jan; 77(1):36-43. PubMed ID: 3284218
[TBL] [Abstract][Full Text] [Related]
7. Pirsidomine, a novel nitric oxide donor, suppresses ischemic arrhythmias in anesthetized pigs.
Wainwright CL; Martorana PA
J Cardiovasc Pharmacol; 1993; 22 Suppl 7():S44-50. PubMed ID: 7504768
[TBL] [Abstract][Full Text] [Related]
8. Potassium channel openers and blockers in coronary artery disease. Comparison to betablockers and calcium antagonists.
Mitrovic V; Oehm E; Thormann J; Pitschner H; Hamm C
Herz; 2000 Mar; 25(2):130-42. PubMed ID: 10829253
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized, placebo-controlled study of molsidomine in patients with stable effort angina receiving beta-blocker therapy with atenolol.
De Backer GG; Derese A
Am Heart J; 1985 Mar; 109(3 Pt 2):678-81. PubMed ID: 3883735
[TBL] [Abstract][Full Text] [Related]
10. Discordance between effects of anti-ischemic therapy on ambulatory ischemia, exercise performance and anginal symptoms in patients with stable angina pectoris. The Angina and Silent Ischemia Study Group (ASIS).
Borzak S; Fenton T; Glasser SP; Shook TL; MacCallum G; Young PM; Stone PH
J Am Coll Cardiol; 1993 Jun; 21(7):1605-11. PubMed ID: 8496526
[TBL] [Abstract][Full Text] [Related]
11. Discordance of anti-ischemic and hemodynamic effects of captopril in stable coronary artery disease.
Winkelmann BR; Matheis G; Kleist P; Pötter S; Wohltmann D; Kaltenbach M
Coron Artery Dis; 1994 Oct; 5(10):829-44. PubMed ID: 7866603
[TBL] [Abstract][Full Text] [Related]
12. [Effect duration and dose-response relation of molsidomine in patients with coronary heart disease].
Fach WA; Becker HJ
Z Kardiol; 1984 Oct; 73(10):613-22. PubMed ID: 6393621
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina.
Kuhn A; Carlsson J; Miketic S; Tebbe U
Cardiovasc Drugs Ther; 1995 Aug; 9(4):595-600. PubMed ID: 8547210
[TBL] [Abstract][Full Text] [Related]
14. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina.
Chen JW; Lee WL; Hsu NW; Lin SJ; Ting CT; Wang SP; Chang MS
Am J Cardiol; 1997 Jul; 80(1):32-8. PubMed ID: 9205016
[TBL] [Abstract][Full Text] [Related]
15. Differential hemodynamic effects of the nitric oxide donor pirsidomine in comparison to SIN-1, nitroprusside and nitroglycerin.
Arkonac BM; Kersten JR; Wynsen JC; Nijhawan N; Warltier DC
Pharmacology; 1996 Feb; 52(2):92-100. PubMed ID: 8851630
[TBL] [Abstract][Full Text] [Related]
16. Exercise tolerance in coronary patients: randomized trial of two-week treatment with molsidomine versus placebo.
Messin R
Am Heart J; 1985 Mar; 109(3 Pt 2):667-9. PubMed ID: 3883732
[TBL] [Abstract][Full Text] [Related]
17. A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations.
Messin R; Fenyvesi T; Carreer-Bruhwyler F; Crommen J; Chiap P; Hubert P; Dubois C; Famaey JP; Géczy J
Eur J Clin Pharmacol; 2003 Jul; 59(3):227-32. PubMed ID: 12734607
[TBL] [Abstract][Full Text] [Related]
18. [Does captopril possess antianginal actions? An evaluation of its effects on myocardial ischemia by stress tests in patients with stable angina and normal ventricular function].
Poveda Sierra JJ; Berrazueta JR; Ochoteco A; Salas E
Rev Esp Cardiol; 1993 Oct; 46(10):642-7. PubMed ID: 8234999
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effects of molsidomine at rest and during submaximal and maximal exercise in patients with coronary artery disease limited by exertional angina pectoris.
Detry JM; Melin J; Brasseur LA; Cosyns J; Rousseau MF
Am J Cardiol; 1981 Jan; 47(1):109-15. PubMed ID: 6893896
[TBL] [Abstract][Full Text] [Related]
20. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris.
Wallace WA; Wellington KL; Chess MA; Liang CS
Am J Cardiol; 1994 Jan; 73(1):23-8. PubMed ID: 8279372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
